HOME >> BIOLOGY >> NEWS
Experimental drug decreases age-related blood vessel stiffening

An experimental drug may reverse stiffening of the cardiovascular system that occurs with aging, according to a national study led by Johns Hopkins physicians.

In a group of older people with vascular stiffening, the drug, ALT-711, significantly reduced arterial pulse pressure, defined as the difference between systolic blood pressure (the upper number) and diastolic blood pressure (the lower number). It also improved the blood vessels' ability to stretch by about 14 percent. Results are to be reported in the Sept. 25 issue of Circulation, an American Heart Association journal, but were posted online Sept. 3. ALT-711 is manufactured by Alteon Inc., Ramsey, N.J.

Vascular stiffening and its related increase in the heart's workload is a "huge epidemiological problem," affecting about half of all individuals over age 60, says David A. Kass, M.D., lead author of the study and professor of medicine and biomedical engineering at Hopkins. "Many recent epidemiological studies have shown that pulse pressure is the leading risk factor for cardiovascular disease in the elderly," he says. Left untreated, the condition can lead to high blood pressure, congestive heart failure, heart attack and other disorders.

ALT-711 works by breaking up chemical links between sugar and proteins called advanced glycosylated (sugar-based) crosslink endproducts, or AGE. In the cardiovascular system, AGE results in a loss of artery elasticity. This leads to an increase in the blood pressure pulse and selective rise in the systolic pressure, putting patients at an increased risk of heart attack, heart failure and coronary artery disease.

The crosslinks form in patients with abnormal sugar control such as diabetics but also with normal aging. They particularly target long-lived proteins, like those that make up the structure of artery walls and are responsible for their ability to stretch. The more crosslinks, the stiffer the related tissues. This affec
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
5-Sep-2001


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental Biology 2003 meets in San Diego April 11-15
10. Experimental gene switch increases lifespan with no ill effects
11. Experimental therapy stops allergic reactions in mice

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this ... high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered fume ... hoods in the laboratory. , Attendees will learn from an industry expert about ...
(Date:9/19/2017)... ... ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured in an ... A Rising Tide". Dr. Harman and Dr. Riordan met in 2003 and have remained ... potential of stem cell therapy and a fast friendship was formed. , Dr. Harman has ...
(Date:9/19/2017)... ... September 19, 2017 , ... One of the ... be eliminated, said Lyle Probst, President, CEO and Founder of ExcitePCR ™. ... other pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX ...
(Date:9/19/2017)... ... September 19, 2017 , ... Avomeen Analytical Services, ... of its 2017 Science Student Award. The scholarship program is dedicated to helping ... service defray the costs of obtaining their science education. , Avomeen began the ...
Breaking Biology Technology:
Cached News: